Search clinical trials for: olmesartan medoxomil placebo candesartan cilexetil

Total 251 results

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Institut für Pharmakologie und Präventive Medizin

Completed

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg (Sevicontrol-2)

Hypertension

Germany
Daiichi Sankyo, Inc.

Completed

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Hypertension

United States, Colombia, Argentina, Peru, Brazil, Kenya, Chile, South Africa, India, Zambia, Uganda
Lee's Pharmaceutical Limited

Completed

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Hypertension

China
Biomedis International Ltd.

Unknown

Recurrent Stroke Prevention Clinical Outcome Study (RESPECTS)

Stroke | Hypertension | Blood Pressure

Japan
Institut für Pharmakologie und Präventive Medizin

Completed

Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine (Sevicontrol1)

Hypertension

Germany
AstraZeneca

Completed

ARIA (Atacand Renoprotection In NephropAthy Pt.) (PCR)

Non-diabetic Nephropathy With Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Hypertension

India
Ullevaal University Hospital
Takeda; AstraZeneca; Southern-Eastern Norway Health Authorities RHF

Completed

Scandinavian Candesartan Acute Stroke Trial (SCAST)

Stroke

Norway
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions

Hypertension

India
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Daiichi Sankyo, Inc.

Completed

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Atherosclerosis
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
GlaxoSmithKline

Completed

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Cardiovascular Disease

India
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension

China
Takeda

Completed

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Essential Hypertension
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Tohoku University

Completed

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT)

Chronic Heart Failure

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Diabetic Nephropathy | Chronic Glomerulonephritis

Japan
Central South University

Completed

Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

Drug Interaction of Olmesartan in Healthy Chinese Volunteers

China
AstraZeneca

Completed

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Proteinuria

Canada
Takeda

Completed

A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

Type 2 Diabetes Mellitus and Microalbuminuria

Japan
Bayer

Withdrawn

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Hypertension

Italy
Huazhong University of Science and Technology

Unknown

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Hypertension

China
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Diabetes Mellitus

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Kidney Disease

Germany
Takeda

Completed

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

Hypertension
Virginia Polytechnic Institute and State University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Angiotensin II Blockade and Inflammation in Obesity (ARB)

Hypertension | Overweight | Prehypertension | Obese
Boryung Pharmaceutical Co., Ltd

Completed

Fimasartan Achieving SBP Target (FAST) Study (FAST)

Essential,Hypertension

Korea, Republic of
Norwegian University of Science and Technology
AstraZeneca

Completed

Prophylactic Treatment of Episodic Cluster Headache

Cluster Headache

Norway
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Takeda

Completed

Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」

Hypertension

Japan
AstraZeneca
Takeda

Completed

Diabetic Retinopathy Candesartan Trials (DIRECT)

Type 1 Diabetes

Denmark, Australia
Daiichi Sankyo, Inc.

Completed

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Hypertension

United States
Takeda

Completed

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Safety

Ukraine, Germany, Poland, Bulgaria, Netherlands, Lithuania, Slovakia, Latvia
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

Olmesartan Pediatric Pharmacokinetic (PK) Study

Hypertension

United States
Pfizer

Completed

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Hypertension
University of Sydney
The George Institute for Global Health, India

Terminated

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (CLARITY 2)

COVID-19 | SARS-CoV2 Infection

India
AstraZeneca

Completed

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

Hypertension

United States, France, Italy, United Kingdom, Germany, Poland, Ukraine, Belgium, Puerto Rico, Denmark
AstraZeneca

Completed

Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age

Hypertension

United States, Hungary, Slovakia, Belgium
AstraZeneca

Completed

Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age

Pediatric Hypertension

United States, Hungary, Slovakia, Belgium
AstraZeneca

Completed

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) (HIP)

Hypertension

France, Germany, Poland, Ukraine, Belgium, Italy
Abbott
Datamap; ClinIntel; Catalent; Nuvisan

Withdrawn

A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2

Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2

Germany, Spain
Shenzhen People's Hospital

Recruiting

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Essential Hypertension

China
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil and Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria | Renal Disease

Poland, Spain, Estonia, Czech Republic, Germany, Slovakia, Netherlands
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Hypertension

United States
Daiichi Sankyo, Inc.

Completed

Olmesartan Comparison to Losartan in Hypertensive Subjects

Hypertension

United States

3

Subscribe